Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis

CTLT vs. ZTS: Which Stock Is the Better Value Option?

Here's Why Catalent Stock Soared 73.9% in the First Half of 2019

Catalent (CTLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock?

Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.

Catalent Acquires Gene Therapy Leader Paragon Bioservices

Catalent (CTLT) delivered earnings and revenue surprises of 8.89% and -4.14%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Surpasses Q3 Earnings Estimates

Gene therapy deal news continues to trickle in after Catalent Inc (NYSE: CTLT) announced an agreement to buy another gene and cell therapy CDMO.

Catalent Agrees To Buy Gene Therapy-Focused CDMO Paragon Services For $1.2B

Catalent Inc. said Monday it has agreed to acquire Paragon Bioservices Inc. for $1.2 billion in cash.

Catalent to acquire Paragon Bioservices for $1.2 billion in cash

Catalent said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion.

Catalent reportedly to buy Paragon Bioservices for $1.2 billion

CTLT vs. ORINY: Which Stock Is the Better Value Option?

CTLT or ORINY: Which Is the Better Value Stock Right Now?

News for Catalent Stock (CTLT)